Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Achilles Therapeutics (ACHL)
NASDAQ:ACHL
Holding ACHL?
Track your performance easily
ACHL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.63 - $1.76
Previous Close$0.94
Volume1.96M
Average Volume (3M)579.28K
Market Cap
$38.62M
Enterprise Value-$88.30M
Total Cash (Recent Filing)$131.54M
Total Debt (Recent Filing)$4.62M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 05, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,082,948
10 Day Avg. Volume3,414,907
30 Day Avg. Volume579,282
Standard Deviation0.19
R-Squared0.11
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda2.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Achilles Therapeutics News
PremiumCompany Announcements
Achilles Therapeutics Shifts Strategy, Seeks Alternatives
PremiumPress Releases
Achilles Therapeutics Announces Strategic Update
PremiumCompany Announcements
Achilles Therapeutics Excels in Q2 with Promising Trials
PremiumCompany Announcements
Leadership Shift at Achilles Therapeutics
PremiumCompany Announcements
Achilles Therapeutics AGM Concludes with Key ApprovalsOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.23% Mutual Funds
51.07% Other Institutional Investors
48.70% Public Companies and
Individual Investors
ACHL FAQ
What was Achilles Therapeutics’s price range in the past 12 months?
Achilles Therapeutics lowest stock price was $0.63 and its highest was $1.76 in the past 12 months.
What is Achilles Therapeutics’s market cap?
Currently, no data Available
When is Achilles Therapeutics’s upcoming earnings report date?
Achilles Therapeutics’s upcoming earnings report date is Nov 05, 2024 which is in 45 days.
How were Achilles Therapeutics’s earnings last quarter?
Achilles Therapeutics released its earnings results on Aug 14, 2024. The company reported -$0.41 earnings per share for the quarter, the consensus estimate of -$0.41 by $0.
Is Achilles Therapeutics overvalued?
According to Wall Street analysts Achilles Therapeutics’s price is currently Overvalued.
Does Achilles Therapeutics pay dividends?
Achilles Therapeutics does not currently pay dividends.
What is Achilles Therapeutics’s EPS estimate?
Achilles Therapeutics’s EPS estimate is -$0.41.
How many shares outstanding does Achilles Therapeutics have?
Achilles Therapeutics has 41,087,902 shares outstanding.
What happened to Achilles Therapeutics’s price movement after its last earnings report?
Achilles Therapeutics reported an EPS of -$0.41 in its last earnings report, expectations of -$0.41. Following the earnings report the stock price went down -1.299%.
Which hedge fund is a major shareholder of Achilles Therapeutics?
Among the largest hedge funds holding Achilles Therapeutics’s share is Baker Bros Advisors LP. It holds Achilles Therapeutics’s shares valued at 904K.
---
Achilles Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 100.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.79%
12-Months-Change
Fundamentals
Return on Equity
-44.27%
Trailing 12-Months
Asset Growth
-33.71%
Trailing 12-Months
Company Description
Achilles Therapeutics
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
---
ACHL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering ACHL
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-46.01%
reiterated a buy rating 6 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -46.01% per trade.
---